Apophar SRL
6.4 FTEApophar reported total assets of €5.33m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Aug 2026), with 6.4 full-time equivalents.
The score of Apophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +57 % Total assets +25 % Headcount (avg FTE) +12 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apophar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Aug 2026
- Year ended 31 Dec 2024filed on 28 Sep 2025
- Year ended 31 Dec 2023filed on 15 Oct 2024
- Year ended 31 Dec 2022filed on 25 Dec 2023
- Year ended 31 Dec 2021filed on 15 Feb 2023
Apophar's financial analysis
- Solvency13.1%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apophar
Apophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0768.405.096
- VAT number
- BE0768405096
- Peppol
- Registered · 0208:0768405096 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 May 2021
- Registered office
- 1050 Ixelles
- Size
- Micro · 6.4 FTE
- Latest accounts
- 2025 · filed on 22 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apophar (SRL) has been based in Ixelles since 2021, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 3,132 € and equity of 697,083 €; its revenue is not published. With 6.4 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 13.1%, below the median of its sector (37.8%).
Companies similar to Apophar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Bourguignon-Deraeve Retail sale of pharmaceutical products Ninove · balance sheet €5.34m
- Alpaga MDB Retail sale of pharmaceutical products Kontich · balance sheet €5.32m
- Dermatheek Retail sale of pharmaceutical products Ranst · balance sheet €5.46m
- Imbefrance Retail sale of pharmaceutical products Halle · balance sheet €5.11m
- Pharmacie Anselme Retail sale of pharmaceutical products Antoing · balance sheet €4.76m
- Pharmalliance Retail sale of pharmaceutical products Lasne · balance sheet €6.38m
- Nerum Retail sale of pharmaceutical products Heusden-Zolder · balance sheet €6.46m
- Palatine Retail sale of pharmaceutical products Etterbeek · balance sheet €6.58m
Frequently asked questions about Apophar
What is the revenue of Apophar?
Apophar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0768405096 for Apophar, if the company is VAT-registered. Its company number (CBE) is 0768.405.096.
Where is the registered office of Apophar?
According to the CBE register, the registered office of Apophar is in 1050 Ixelles.
What is the equity of Apophar?
At the close of the 2025 financial year, the equity of Apophar amounts to 697,083 €, a solvency of 13.1% of total assets.
How many people work at Apophar?
6.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Apophar?
The register lists 2 active mandates at Apophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →